RadNet RDNT
United StatesHealthcare · Diagnostics & ResearchUSD
94.62 USD (+37.9%)
8 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
RadNet, Inc. is the largest provider of outpatient diagnostic imaging services in the United States, operating a network of medical imaging centers (MRI, CT, mammography, etc.) and offering teleradiology services and AI solutions for diagnostics.
Key points
from its scores- ✕Little or no dividend1.5
- ✕Demanding valuation3.2
- ✕Fragile balance sheet3.3
AI analysis
bottom line, main risk, context and newsThe combination of high leverage, low profitability, and demanding valuation does not justify new positions until the balance sheet is deleveraged or profitability improves.
RadNet shows very strong revenue growth (25%), but its profitability is poor (ROE 1.50%, operating margin 7.89%) and its balance sheet is highly leveraged (Net Debt/EBITDA of 5.28), which, combined with a demanding valuation (forward P/E 77.38), makes it vulnerable to a rising rate environment.
The main risk is financial: high leverage (Net Debt/EBITDA of 5.28) in a rising interest rate environment could strain cash flow and limit investment capacity, especially if revenue growth decelerates.
Context and risks
RadNet operates in the diagnostic imaging sector in the US, a market with moderate regulatory risk due to dependence on Medicare/Medicaid reimbursements and the need for state approvals for center expansion. The company has high leverage (Net Debt/EBITDA of 5.28), which amplifies its sensitivity to a rising interest rate environment, although its debt is mostly in dollars and its business is domestic, limiting direct geopolitical exposure.
Is RadNet stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 79% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 25.9 | 14.5 | +79% |
| Price / book | 5.0 | 4.1 | +21% |
| Price / sales | 2.4 | 3.4 | −30% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.2 out of 10 (median for Healthcare: 4.7).
Average analyst target: 94.62 USD, +37.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 4.3 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 77.4
- EV / EBITDA
- 25.9
- Price / book
- 5.0
- Price / sales
- 2.4
- PEG
- 0.96
- Market cap
- 5.4B USD
- Enterprise value
- 7.2B USD
Profitability
- ROE
- 1.5%
- ROA
- 1.7%
- ROIC (approx.)
- 5.5%
- Gross margin
- 17.3%
- Operating margin
- 7.9%
- Net margin
- −0.9%
- Free cash flow
- 157.7M USD
- FCF yield
- 2.9%
- Cash conversion
- 57%
Solvency
- Total debt
- 2.2B USD
- Net debt
- 1.5B USD
- Cash
- 726.3M USD
- EBITDA
- 276.1M USD
- Net debt / EBITDA
- 5.28
- Debt / equity
- 156.67
- Current ratio
- 1.48
- Quick ratio
- 1.39
Growth
- Revenue growth
- +25.0%
- Earnings growth
- −49.1%
- EPS (TTM)
- −0.27 USD
- EPS (forward)
- 0.89 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.41
- Analyst consensus
- none (8)
- Target price
- 94.62 USD
- 52-week range
- 50.82 – 85.84
Recent news
All RDNT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about RadNet
Is RadNet stock cheap or expensive?
On EV / EBITDA, it trades 79% above the Healthcare median. Valuation score: 3.2 out of 10 (median for Healthcare: 4.7). Average analyst target: 94.62 USD, +37.9% versus the price. This is not investment advice.
What score does RadNet get on MeridIAn Screener?
It scores 3.5 out of 10, rank 2,035 of 2,130 (better than 4% of the companies analysed). Its strongest category is Momentum (5.2) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
How much is RadNet worth on the stock market?
Its market capitalisation is 5.4B USD and its enterprise value, debt included, is 7.2B USD.
How much debt does RadNet have?
Its net debt (debt minus cash) is 1.5B USD. That is 5.28 times its EBITDA; the Healthcare median is 1.53.
Does RadNet pay a dividend?
It pays no dividend, or almost none.
How has RadNet stock performed over the last year?
It has fallen 2.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 50.82 and 85.84 USD. Past performance does not guarantee future results.
What do analysts think of RadNet?
8 analysts cover it; their average recommendation is “none” and their average target is 94.62 USD (+37.9% versus the price). It is an estimate, not market data.